Scientific Resources in Clinical Development

Altasciences’ clinical experts have developed an extensive resource library to guide you through all phases of early drug development, from lead candidate selection to clinical proof of concept, and beyond.

Webinars:

	The Golden Era of GLP-1 Drugs Dive deep into the mechanisms, benefits, and clinical applications of GLP-1 drugs.
	A Hop Across the Pond-Discovering the Many Advantages of Conducting Early Phase Clinical Trials in North America Discover the key advantages of conducting clinical trials in North America.
	Inside the Pharmacodynamic Toolbox: How Questionnaires, Models, and Tests of Cognition Can Accelerate the Development of CNS-Active Drugs Explore the flexible selection of pharmacodynamic measures to enhance the pharmacology, safety, and efficacy evaluation of a CNS-active drug in early clinical trials.
	The Path Forward, Altasciences’ Approach to Project Management Learn about our unique approach that can lower your costs and reduce programme timelines by up to 40 percent, from lead candidate selection to clinical proof-of-concept.

The Altascientist—A Scientific Journal:

	Managing the Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development Dive into the dynamic world of glucagon-like peptide-1 receptor agonists (GLP-1 RA), where we explore the current landscape, the challenges ahead, and the complexities of early-phase drug development.
	End-to-End CNS Drug Development Solutions Explore the complexities of CNS drug development programmes and how partnering with an integrated CRO/CDMO can help you move your molecule seamlessly from one phase to the next. Case studies included!
	The Advantages of Conducting Early Phase Clinical Research in Canada In light of the regulatory constraints in Europe, discover the benefits (including time and cost savings) and ease of conducting early phase research in Canada.
	Shortening Drug Development Timelines With Asian Ethnobridging Trials Learn how an Asian ethnobridging strategy reduces drug development costs, and shortens the NDA timeline when it includes conducting necessary analyses in Asian subjects during Phase I studies.
	Planning your First-in-Human Trial This issue serves as a broad roadmap for successfully conducting first-in-human (FIH) studies.